

[54] **METHOD FOR REDUCING BLOOD PRESSURE LEVELS IN HYPERTENSIVE PERSONS**

[75] **Inventor:** **Barry D. Sears, Swampscott, Mass.**

[73] **Assignee:** **BioSyn, Inc., Marblehead, Mass.**

[21] **Appl. No.:** **539,384**

[22] **Filed:** **Jun. 18, 1990**

Related U.S. Application Data

[60] Division of Ser. No. 400,288, Aug. 29, 1989, abandoned, which is a continuation-in-part of Ser. No. 251,139, Sep. 28, 1988, abandoned.

[51] **Int. Cl.⁵** **A61K 31/22; A61K 31/20; A61K 31/23**

[52] **U.S. Cl.** **514/549; 514/552; 514/560**

[58] **Field of Search** **514/552, 560, 558, 549**

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,681,896 7/1987 Horrobin 514/560
4,920,098 4/1990 Cotter et al. 514/558

Primary Examiner—Frederick E. Waddell
Assistant Examiner—Raymond J. Henley, III
Attorney, Agent, or Firm—Richard P. Crowley

[57] **ABSTRACT**

The modulation of prostaglandin levels can be realized through the dietary intake of specified ratios of activated Omega 6 essentially fatty acids when combined with the appropriate amount of eicosapentaenoic acid (EPA), an Omega 3 fatty acid. The modulation of prostaglandins levels can be determined by changes in physiological parameters which are related to prostaglandin levels in mammals. Certain ratios of activated Omega 6 essentially fatty acids and EPA can have significant physiological benefits, whereas other ratios demonstrate detrimental physiological effects in mammals.

8 Claims, 1 Drawing Sheet